VAMAS6
MCID: VTL009
MIFTS: 42

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (VAMAS6)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

MalaCards integrated aliases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

Name: Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 57 13
Generalized Vitiligo 73 71
Vitiligo 73 71
Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 71
Vamas6 57
Vtlg 73

Characteristics:

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
? epistatically interacting multiple autosomal recessive


HPO:

31
vitiligo-associated multiple autoimmune disease susceptibility 6:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM® 57 193200
MeSH 44 D014820
UMLS 71 C0042900 C1304470 C1847835

Summaries for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

UniProtKB/Swiss-Prot : 73 Vitiligo: A pigmentary disorder of the skin and mucous membranes. It is characterized by circumscribed depigmented macules and patches, commonly on extensor aspects of extremities, on the face or neck and in skin folds. Vitiligo is a progressive disorder in which some or all of the melanocytes in the affected skin are selectively destroyed. It is a multifactorial disorder with a complex etiology probably including autoimmune mechanisms, and is associated with an elevated risk of other autoimmune diseases.

MalaCards based summary : Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6, also known as generalized vitiligo, is related to vitiligo-associated multiple autoimmune disease susceptibility 1 and spastic paraplegia 23, autosomal recessive, and has symptoms including pruritus and exanthema. An important gene associated with Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 is PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22). The drugs mometasone furoate and Fluticasone have been mentioned in the context of this disorder. Affiliated tissues include skin, thyroid and t cells, and related phenotypes are vitiligo and nevus

More information from OMIM: 193200

Related Diseases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Diseases in the Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 family:

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 630)
# Related Disease Score Top Affiliating Genes
1 vitiligo-associated multiple autoimmune disease susceptibility 1 12.0
2 spastic paraplegia 23, autosomal recessive 11.5
3 deafness, congenital, with vitiligo and achalasia 11.5
4 autoimmune disease 1 11.4
5 alopecia areata 11.3
6 alopecia universalis onychodystrophy vitiligo 11.2
7 alezzandrini syndrome 11.1
8 autoimmune disease 2 11.1
9 autoimmune disease 3 11.1
10 autoimmune disease 4 11.1
11 schrander-stumpel theunissen hulsmans syndrome 11.1
12 vogt-koyanagi-harada disease 11.0
13 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 11.0
14 autoimmune polyglandular syndrome type 3 11.0
15 stiff-person syndrome 11.0
16 familial cold autoinflammatory syndrome 3 11.0
17 halo nevus 10.9
18 vitiligo, progressive, with mental retardation and urethral duplication 10.9
19 hereditary spastic paraplegia 23 10.9
20 hemifacial atrophy, progressive 10.9
21 autoimmune atrophic gastritis 10.9
22 ermine phenotype 10.8
23 combined cellular and humoral immune defects with granulomas 10.8
24 nijmegen breakage syndrome 10.8
25 lelis syndrome 10.8
26 t-cell receptor-alpha/beta deficiency 10.8
27 hypopigmentation of eyelid 10.8
28 gemignani syndrome 10.8
29 pigmentation anomaly of the skin 10.8
30 skin disease 10.8
31 autoimmune disease 10.7
32 alopecia 10.7
33 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.7
34 melanoma 10.7
35 psoriasis 10.6
36 pustulosis of palm and sole 10.6
37 thyroiditis 10.6
38 hypothyroidism 10.6
39 dowling-degos disease 1 10.5
40 dermatitis 10.5
41 skin carcinoma 10.4
42 dermatitis, atopic 10.4
43 hashimoto thyroiditis 10.4
44 lichen planus 10.4
45 halo nevi 10.4
46 thyroid gland disease 10.3
47 pernicious anemia 10.3
48 graves' disease 10.3
49 uveitis 10.3
50 systemic scleroderma 10.3

Graphical network of the top 20 diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:



Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Symptoms & Phenotypes for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Human phenotypes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

31
# Description HPO Frequency HPO Source Accession
1 vitiligo 31 HP:0001045
2 nevus 31 HP:0003764

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Skin:
vitiligo
halo nevi

Misc:
onset after birth
no predilection for ventral skin

Clinical features from OMIM®:

193200 (Updated 05-Mar-2021)

UMLS symptoms related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:


pruritus, exanthema

Drugs & Therapeutics for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Drugs for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
2
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
3
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
4
Dinoprost Approved, Investigational Phase 4 551-11-1 5283078
5
Dinoprost tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
6
Travoprost Approved Phase 4 157283-68-6 5282226
7
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
8 Anti-Allergic Agents Phase 4
9 Bronchodilator Agents Phase 4
10 abobotulinumtoxinA Phase 4
11 Neurotransmitter Agents Phase 4
12 Botulinum Toxins, Type A Phase 4
13 Botulinum Toxins Phase 4
14 Cholinergic Agents Phase 4
15 Furocoumarins Phase 4
16
Latanoprost Approved, Investigational Phase 2, Phase 3 130209-82-4 5282380 5311221
17
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
18
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492 6473866
19
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
20 Janus Kinase Inhibitors Phase 3
21 Immunosuppressive Agents Phase 2, Phase 3
22 Immunologic Factors Phase 2, Phase 3
23 Calcineurin Inhibitors Phase 2, Phase 3
24 triamcinolone acetonide Phase 2, Phase 3
25 Hormone Antagonists Phase 2, Phase 3
26 Triamcinolone hexacetonide Phase 2, Phase 3
27 Triamcinolone diacetate Phase 2, Phase 3
28 Hormones Phase 2, Phase 3
29 glucocorticoids Phase 2, Phase 3
30
Hydrocortisone acetate Approved, Vet_approved Phase 1, Phase 2 50-03-3
31
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 5754
32
Simvastatin Approved Phase 2 79902-63-9 54454
33
Etanercept Approved, Investigational Phase 2 185243-69-0
34
Afamelanotide Approved, Investigational Phase 2 75921-69-6
35
Pimecrolimus Approved, Investigational Phase 2 137071-32-0 6447131 17753757
36
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
37
Atorvastatin Approved Phase 1, Phase 2 134523-00-5 60823
38
Tofacitinib Approved, Investigational Phase 2 477600-75-2
39
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
40
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
41
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
42 Anti-Inflammatory Agents Phase 1, Phase 2
43 Hydrocortisone 17-butyrate 21-propionate Phase 1, Phase 2
44 Hydrocortisone hemisuccinate Phase 1, Phase 2
45 Hydrocortisone-17-butyrate Phase 1, Phase 2
46 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
47 Hypolipidemic Agents Phase 2
48 Lipid Regulating Agents Phase 2
49 Anticholesteremic Agents Phase 2
50 Analgesics, Non-Narcotic Phase 2

Interventional clinical trials:

(show top 50) (show all 145)
# Name Status NCT ID Phase Drugs
1 Autologous Punch Grafting in Vitiligo Patients: the Effect of Punchdepth and Punchsize Unknown status NCT01377077 Phase 4
2 Comparison the Efficacy and Safety of 0.1% Tacrolimus Ointment With 0.1% Mometasone Furoate Cream in the Treatment of Adult Vitiligo: A Single Blinded Pilot Study Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
3 Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) Unknown status NCT01082393 Phase 4 topical tacrolimus treatment;topical pimecrolimus treatment;local mometasone furoate treatment;cold cream
4 Bimatoprost 0.03% Solution, NB-UVB and Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo Unknown status NCT03487042 Phase 4 Bimatoprost 0.03% ophthalmic solution
5 Effect of Fluticasone Proprionate 0.05% Cream on Narrow Band UV-B Phototherapy in Active Vitiligo: a Randomised Single Blinded Controlled Trial Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
6 Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo Unknown status NCT03199664 Phase 4
7 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Pilot Study Unknown status NCT01640678 Phase 4
8 Botulinum Toxin Treatment for Localized Vitiligo Completed NCT01051687 Phase 4 Botulinum toxin A
9 Prospective Open Parallel Right to Left Bilateral Study Comparing Narrowband Ultraviolet B Alone Versus Narrowband Ultraviolet B and Psoralen Plus Ultraviolet A for the Treatment of Vitiligo Completed NCT01732965 Phase 4
10 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Study on the Recipient Site Preparation Completed NCT02458417 Phase 4
11 Safety And Efficacy Of Topical Prostaglandin F2α Analogs In Combination With Fractional CO2 Laser And 308 Excimer Light In Treatment Of Vitiligo Not yet recruiting NCT04577027 Phase 4 Topical travoprost 0.004% solution
12 Efficacy and Safety of Topical Bimatoprost Solution 0.03% in Stable Vitiligo:A Preliminary Study Withdrawn NCT01202513 Phase 4 Bimatoprost 0.03% topical ophthalmic solution
13 Effectiveness of Microneedling and Topical Latanoprost in Treatment of Acrofacial Vitiligo Unknown status NCT03611348 Phase 2, Phase 3 Latanoprost
14 Continuative vs Sequential Phototherapy in Non-segmental Vitiligo Patients Unknown status NCT00525395 Phase 3
15 Efficacy of Tacrolimus Ointment 0.1% Versus Placebo in Adults With Facial Non-segmental Vitiligo: a Randomized Double-blind Controlled Study Unknown status NCT02466997 Phase 3 tacrolimus;Placebo
16 Treatment of Vitiligo With Narrowband UVB (TL01) Combined With Tacrolimus (0.1%) Versus Placebo Ointment, a Randomized Right/Left Double Blind Comparative Study Completed NCT00807690 Phase 3 Tacrolimus ointment
17 Safety and Efficacy of Melanocyte-keratinocyte Transplantation in the Treatment of Vitiligo Completed NCT00830713 Phase 3
18 Efficacy and Tolerance of Transplantation of Harvested Epidermal Cells and Narrow-Band UVB in Vitiligo Completed NCT01629979 Phase 2, Phase 3
19 Interest of the Dermabrasion by Laser Erbium in the Treatment of the Vitiligo Completed NCT01087216 Phase 2, Phase 3 Bras B : The group control
20 A Multicenter Double-blind Placebo-controlled Trial of Non-cultured Epidermal Cellular Grafting Versus Hyaluronic Acid for Repigmenting Stable Leukoderma (Vitiligo and Piebaldism) Completed NCT02156427 Phase 3
21 Comparative Study of 308nm Excimer Lamp and 308nm Excimer Laser in the Treatment of Vitiligo Completed NCT00696358 Phase 3
22 Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin Completed NCT00631865 Phase 3
23 A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo Recruiting NCT04530344 Phase 3 ruxolitinib;Vehicle
24 Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo Active, not recruiting NCT04052425 Phase 3 Ruxolitinib cream;Vehicle
25 Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo Active, not recruiting NCT04057573 Phase 3 Ruxolitinib cream;Vehicle
26 Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo Terminated NCT02191748 Phase 2, Phase 3 Triamcinolone
27 Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control, Randomized and Double Blind Study Terminated NCT01841008 Phase 2, Phase 3 Protopic;Placebo : Diprobase
28 Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study of the Efficacy and Safety of ACH24 in the Treatment of Vitiligo Withdrawn NCT01419964 Phase 3 Group 01;Group 02
29 Comparative Study of the Use of Trypsin Versus Dispase in Melanocyte-Keratinocyte Transplantation for the Treatment of Vitiligo Withdrawn NCT01822379 Phase 2, Phase 3
30 UVA 1 Phototherapy for Vitiligo Unknown status NCT01787695 Phase 2
31 Treatment and Complication of Bath PUVA in Vitiligo Unknown status NCT00380471 Phase 2
32 Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand: A Prospective Randomized, Single-blinded Controlled Clinical Trial Unknown status NCT01792245 Phase 2
33 Efficacy and Safety of Intralesional Triamcinolone Acetonide in Vitiligo: A Prospective, Double-Blind Randomized Controlled Trial Unknown status NCT01766609 Phase 2 Triamcinolone Acetonide
34 Efficacy of Red Light in Vitiligo: A Prospective, Single-Blind Randomized Controlled Trial Unknown status NCT01787708 Phase 2
35 Effectivness of Topical Tacrolimus 0.03% Monotherapy in Patients With Vitiligo: Arandomized Controlled Trial Unknown status NCT03358082 Phase 1, Phase 2 Tacrolimus 0.03% Ointment;Hydrocortisone Acetate 1% Ointment
36 A Phase-II, Randomized, Placebo-controlled Trial of Simvastatin in Generalized Vitiligo Completed NCT01517893 Phase 2 Simvastatin;Placebo
37 Pilot, Investigator-Initiated, Proof-of-Concept, Study of the Efficacy and Safety of Etanercept (Enbrel) in Adults With Vitiligo Completed NCT00134368 Phase 2 Etanercept
38 A Phase II Randomised Pilot Study to Compare the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo Completed NCT01382589 Phase 2 Afamelanotide
39 Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO RAPID VITILIGO Completed NCT03036995 Phase 2 Apremilast
40 A Two-Arm, Randomized, Double-Blind, Phase IIb Study to Compare the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants Plus Narrow-Band Ultraviolet B (NB-UVB) Light Source in the Treatment of Nonsegmental Vitiligo AND A Single-Arm, Open Label, Phase IIb Study to Evaluate the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants Plus Narrow-Band Ultraviolet B (NB-UVB) Light Source in the Treatment of Nonsegmental Vitiligo Completed NCT04525157 Phase 2 Afamelanotide;Placebo
41 Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of Vitiligo Completed NCT01511965 Phase 1, Phase 2
42 Open Label Phase 2 Proof-of-concept Pilot Trial of Topical Ruxolitinib in Repigmenting Adult Patients With Vitiligo Completed NCT02809976 Phase 2 Ruxolitinib 1.5% Phosphate Cream
43 An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo Completed NCT03468855 Phase 2 ATI-50002 topical solution
44 Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris Completed NCT00372307 Phase 2 Application of pimecrolimus
45 Phase I-II, Randomized, Intraindividually Placebo Controlled Clinical Trial, to Evaluate the Efficacy of Autologous Melanocyte Transplantion on Amniotic Membrane as a Substrate for Patients With Stable Vitiligo. Completed NCT01701648 Phase 1, Phase 2
46 The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo (EVRAAS) Completed NCT03247400 Phase 1, Phase 2 1% simvastatin-acid sodium salt ointment;1% atorvastatin calcium salt ointment
47 Atorvastatin in Active Vitiligo: a Bicentric Prospective Randomized Trial Completed NCT02432534 Phase 2 Atorvastatin
48 A Split Body Study of the Effects of Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo Completed NCT03123016 Phase 2 Apremilast
49 A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, and Systemic Exposure of Cerdulatinib Gel, 0.37% in Adults With Vitiligo Completed NCT04103060 Phase 2 Cerdulatinib 0.37% gel;Vehicle gel
50 Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial (ITN086AI) Recruiting NCT04338581 Phase 2

Search NIH Clinical Center for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Methoxsalen
monobenzone
Trioxsalen

Genetic Tests for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Anatomical Context for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

MalaCards organs/tissues related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

40
Skin, Thyroid, T Cells, Liver, Lung, Bone, Breast

Publications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Articles related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

(show top 50) (show all 7204)
# Title Authors PMID Year
1
Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. 61 57
20526339 2010
2
Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. 57 61
20410501 2010
3
Vitiligo: complex segregation and linkage disequilibrium analyses with respect to microsatellite loci spanning the HLA. 57 61
11941482 2002
4
Tumor Necrosis Factor-alpha affects melanocyte survival and melanin synthesis via multiple pathways in vitiligo. 61
33517195 2021
5
Hypopigmented Mycosis Fungoides Mimicking Vitiligo. 61
33156019 2021
6
Vitiligo: an update on systemic treatments. 61
33350506 2021
7
Reply to "Elastin fiber but not collagen fiber is decreased dramatically in the dermis of vitiligo patients": possible mechanisms of decreased elastin fibers. 61
33410498 2021
8
PINK1 in normal human melanocytes: first identification and its effects on H2 O2 -induced oxidative damage. 61
32870534 2021
9
Gender differences in psoriasis: a Swiss online psoriasis survey. 61
32281022 2021
10
Babchi oil-induced phytophotodermatitis mimicking burn injury. 61
33299922 2021
11
Cadmium, lead and mercury in the blood of psoriatic and vitiligo patients and their possible associations with dietary habits. 61
33302005 2021
12
Efficacy and safety of oral simvastatin in the treatment of patients with vitiligo. 61
33093072 2021
13
Adults with a more extensive body involvement, moderate to extremely severe vitiligo and a prolonged clinical course have an early onset in childhood in addition to other prognostic factors as compared to individuals with later-onset vitiligo. 61
32812240 2021
14
The Genetic Basis of Vitiligo. 61
32778407 2021
15
5-Fluorouracil in Dermatology: The Diverse Uses Beyond Malignant and Premalignant Skin Disease. 61
33587385 2021
16
Differentially expressed microRNAs in peripheral blood mononuclear cells of non-segmental vitiligo and their clinical significance. 61
33169883 2021
17
Surgical Interventions for Patients With Vitiligo: A Systematic Review and Meta-analysis. 61
33595599 2021
18
Evaluation of the Langerhans cells role in vitiligo and its relationship to narrow band ultraviolet B rays. 61
33609002 2021
19
Assessment of survivin levels in serum in patients with vitiligo: A case-control study. 61
32757267 2021
20
The use of trichloroacetic acid as a depigmenting therapy in universal vitiligo. 61
33197126 2021
21
Efficacy of the combined excimer light and topical calcipotriol for acral vitiligo: a randomised double-blind comparative study. 61
33595885 2021
22
"Mask vitiligo" secondary to frictional dermatitis from surgical masks. 61
33598967 2021
23
A retrospective study of long term follow-up of 2283 vitiligo patients treated by autologous, non-cultured melanocyte-keratinocyte transplantation. 61
33582653 2021
24
Not always vitiligo or pigmentary mosaicism. 61
33559187 2021
25
Immune-modulatory effects of lenalidomide inhibited the progression of lesions in a vitiligo mouse model. 61
33522688 2021
26
The clinical efficacy of treatment using the autologous non-cultured epidermal cell suspension technique for stable vitiligo in 41 patients. 61
31084382 2021
27
Trichloroacetic Acid in Different Concentrations: A Promising Treatment Modality for Vitiligo. 61
32826599 2021
28
Serum level of S100B in vitiligo patients: Is it a marker of disease activity? 61
32951206 2021
29
Die Verwendung von Trichloressigsäure als Depigmentierungstherapie bei Vitiligo universalis. 61
33586888 2021
30
Plateletcrit values may not be higher in patients with vitiligo. 61
33564893 2021
31
Efficacy and safety of tacrolimus 0.1% for the treatment of facial vitiligo: a multicenter randomized, double-blinded, vehicle-controlled study. 61
33549606 2021
32
The efficacy of fractional carbon dioxide laser combined with narrow-band ultraviolet B phototherapy for non-segmental vitiligo: a systematic review and meta-analysis. 61
32572662 2021
33
Simvastatin in vitiligo: an update with recent review of the literature. 61
33554328 2021
34
Reciprocal regulation of interleukin-17A and interleukin-22 secretion through aryl hydrocarbon receptor activation in CD4+ T cells of patients with vitiligo. 61
33456525 2021
35
Association of FOXP3 and GAGE10 promoter polymorphisms and decreased FOXP3 expression in regulatory T cells with susceptibility to generalized vitiligo in Gujarat population. 61
33181260 2021
36
A retrospective analysis of 925 cases of segmental vitiligo in a Chinese Han population. 61
33539593 2021
37
Fluorescence copolymer-based dual-signal monitoring tyrosinase activity and its inhibitor screening via blue-green emission transformation. 61
33068897 2021
38
Various skin manifestations related to inflammatory bowel disease: A nationwide cross-sectional study on the Korean population. 61
33608949 2021
39
Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. 61
33597266 2021
40
Posttraumatic stress disorder and the associated risk of autoimmune skin diseases: A nationwide population-based cohort study. 61
33587564 2021
41
Biobanked human foreskin epithelial cell sheets reduce inflammation and promote wound healing in a nude mouse model. 61
33530972 2021
42
Fentanyl transdermal patches induced chemical leucoderma. 61
33602721 2021
43
Mask-induced Koebner phenomenon and its clinical phenotypes: A multicenter, real-life study focusing on 873 dermatological consultations during COVID-19 pandemics. 61
33527560 2021
44
Lessons Learned from the First Decade of Laser-Assisted Drug Delivery. 61
33464473 2021
45
Identification of the Competing Endogenous RNA Networks in Oxidative Stress Injury of Melanocytes. 61
33471583 2021
46
Comparison of responses of melanocyte lineages from p75(+) and p75(-) human scalp-derived neural crest stem cells under phototherapy. 61
32607713 2021
47
Razor blade: A simple instrument used in epidermal grafting for vitiligo. 61
32320769 2021
48
Ultraviolet light in combination with other therapies for vitiligo: Synergy or necessity? 61
32891783 2021
49
Reply to: "Comment on 'Razor blade, a simple instrument used in epidermic grafting for vitiligo'". 61
32439464 2021
50
Comment on "Razor blade, a simple instrument used in epidermic grafting for vitiligo". 61
32439461 2021

Variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

ClinVar genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KIF1B NM_015074.3(KIF1B):c.4387C>T (p.Arg1463Cys) SNV Uncertain significance 374063 rs757850683 1:10425479-10425479 1:10365421-10365421

UniProtKB/Swiss-Prot genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

73
# Symbol AA change Variation ID SNP ID
1 PTPN22 p.Arg620Trp VAR_022605 rs2476601

Expression for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Search GEO for disease gene expression data for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6.

Pathways for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

GO Terms for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Sources for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....